Predictable Therapeutic  Results for Gastroparesis and Dyspepsia

EGG delivered GMA subtyping improves therapeutic outcomes

  • Proper subtyping of Gastroparesis and Dyspepsia impacts treatment outcomes
  • Personalized AI-powered diagnostics with specialized treatment plans
  • Builds reputation recognition and practice success with higher outcomes

40 Million + Americans Suffer From Gastroparesis and Dyspepsia

  • 3CPM EGG/EVG delivers reproducible reliable subtyping of the underlying disorder
  • AI derived diagnostic threshold is the difference between successful treatment vs failure
  • 3CPM® GMAT® software uniquely detects the 25% GMA subtype group with 93% response to endoscopic pyloric balloon dilation.
  • Identiflies similar response probability to other pyloric therapy such as BOTOX injection, G-Poem and pyloroplasty.

Proper GMA Subtyping assists in surgical therapy selection and outcomes.

  • Quality of the 3 cpm signal directly correlates with normal ICC number and function
  • Gastroenteric Stimulation (GES) works best with normal 3cpm GMA as determined by EGG
  • Detection of sub optimal 3 cpm GMA subtypes helps to limit surgical failures with GES.
  • Hypernormal GMA subtype or subtypes with elevated GMAT threshold scores have pyloric outflow dysfunction.
    • Pre operative recognition and correction will avoid post-op complications or primary surgical treatment failure in GERD or Bariatric procedures.

Non-invasive, EGG/EVG with water load satiety test subtypes GMA.

  • AI-driven Diagnostics, and intuitive EGGSAS software simplify Treatment Decisions, providing answers within minutes.
  • Personally-tailored Treatment Improves Patient Outcomes
  • EGG driven services enhance Community and Regional Reputation and Outreach

Highly cost effective Return on Investment. Find out how quickly you can recoup your investment with our ROI Calculator.

3CPM Company, Inc.
53 Loveton Circle, Suite 203
Sparks Glencoe, Maryland 21152. USA
Tel:  443-906-3276
Copyright - 3CPM Corporation